No Data
Abnormal Fluctuation Statistics of HKEX Connect | May 7
Zhitong HK Stock Connect Proportion Change Statistics | May 6, 2026
Beijing Chunlizhengda Sets Final 2025 Dividend, Clarifies Withholding Tax Rules
Chunli Medical (688236): 1Q revenue experiences short-term fluctuations, but net profit shows steady growth.
The company's revenue/parent company net profit/non-recurring parent company net profit for the first quarter of 2026 were RMB 217 million/RMB 62 million/RMB 59 million, representing year-over-year changes of -5.6%/+6.3%/+11.7%, respectively. We believe that the pressure on revenue was mainly due to overseas factors.
Huachuang Securities: The rise of domestic products is expected to reshape the landscape of surgical robotics, with significant room for growth in both performance and valuation.
Domestic surgical robotics companies have tremendous potential for long-term performance and valuation.
Chunlizhengda Seeks Mandate for Up to 10% H-Share Buyback
Chunli Medical (01858) proposes to reappoint Daxin Certified Public Accountants.
Chunli Medical (01858) announced that, in order to maintain the continuity and stability of audit work, upon the proposal of the Audit Committee of the Board of Directors and the prior approval of all independent directors, the company intends to reappoint Daxin Certified Public Accountants (Special General Partnership) as its financial audit agency for domestic and overseas operations and internal control audit agency for the fiscal year 2026. The term of appointment will commence from the resolution passed at the annual shareholders' meeting in 2025 until the convening of the annual shareholders' meeting in 2026. The Board of Directors has proposed that the shareholders authorize management to negotiate and determine the specific remuneration with Daxin based on the company's audit workload and market price conditions for 2026.